Welcoming Novelty in the Treatment of Coronary Artery Disease: FDA Approves the Use of Drug-Coated Balloon for Angioplasty.
- 1Department of Medicine, King Edward Medical University, Lahore, Pakistan.
- 2Department of Medicine, The Jewish Hospital-Mercy Health, Ohio, USA.
Abstract
Background
Coronary artery disease (CAD) remains a leading cause of morbidity and mortality in the United States, with in-stent restenosis (ISR) posing a significant challenge following percutaneous coronary intervention (PCI). Drug-eluting stents (DES) have been widely used to mitigate ISR; however, until recently, no drug-coated balloon (DCB) catheter had been approved for use in the United States. The US Food and Drug Administration (FDA) has now approved AGENT DCB, a paclitaxel-coated balloon catheter, offering a novel approach to treating ISR.Hypothesis
The approval of AGENT DCB represents a pivotal advancement in PCI, providing an effective alternative to traditional balloon angioplasty for ISR.Methods
This article is an editorial review and does not involve original research, statistical analysis, or software-based evaluations. The findings and discussion are based on the results of the AGENT IDE trial and related literature on the efficacy of DCB catheters in the treatment of ISR.Results
The AGENT IDE trial, a randomized, multicenter study involving 600 participants across 40 US sites, demonstrated that the paclitaxel-coated balloon group had a significantly lower target lesion failure rate at 12 months compared to the uncoated balloon group (17.9% vs. 28.6%, p = 0.003). The reduction was primarily driven by a lower incidence of target lesion revascularization (13.0% vs. 24.7%, p = 0.001) and myocardial infarction related to the target vessel (5.8% vs. 11.1%, p = 0.02). Additionally, no cases of stent thrombosis were observed in the DCB group compared to 3.2% in the control group (p = 0.001), reinforcing the device's safety and efficacy.Conclusions
The FDA approval of AGENT DCB marks a significant milestone in the management of ISR, offering a promising alternative to conventional interventions. With its ability to deliver antiproliferative therapy while avoiding the complications associated with permanent stents, DCB may revolutionize PCI strategies in the United States. Further studies assessing the long-term impact of this technology, as well as its application in broader patient populations, will be essential to solidify its role in clinical practice.
Related
- Clinical Performance and Safety of the Optima Non-compliant Percutaneous Transluminal Coronary Angioplasty Balloon in Contemporary Percutaneous Coronary Intervention: A Multicenter Real-World Study.
- PO114 | A CASE OF ACQUIRED HEMOPHILIA AFTER TAVI AND CORONARY ANGIOPLASTY IN PATIENT WITH ATRIAL FIBRILLATION AND MULTIPLES CARDIOVASCULAR RISK FACTORS – THE ART AND SCIENCE OF THERAPEUTIC CONFLICT
- Percutaneous treatment of iatrogenic left main coronary artery aneurysm with a covered stent
- Modified interventional retrieval of a balloon with transverse rupture during percutaneous transluminal angioplasty of a vascular access： a case report
- Stent retriever angioplasty with the Tigertriever as a bailout strategy for intracranial atherosclerotic disease–related large-vessel occlusion: illustrative cases
BibTeX
@article{hasan2026welcoming,
title = {{Welcoming Novelty in the Treatment of Coronary Artery Disease: FDA Approves the Use of Drug-Coated Balloon for Angioplasty.}},
author = {Abdul Haseeb Hasan and Muhammad Ali Abid and Abubakar Nazir},
journal = {Clinical cardiology},
year = {2026},
month = nov,
doi = {10.1002/clc.70515},
url = {https://europepmc.org/article/MED/42969476},
note = {CC BY},
}
RIS
TY - JOUR
TI - Welcoming Novelty in the Treatment of Coronary Artery Disease: FDA Approves the Use of Drug-Coated Balloon for Angioplasty.
AU - Abdul Haseeb Hasan
AU - Muhammad Ali Abid
AU - Abubakar Nazir
PY - 2026
DA - 2026/11/01
JO - Clinical cardiology
DO - 10.1002/clc.70515
UR - https://europepmc.org/article/MED/42969476
AB - Background Coronary artery disease (CAD) remains a leading cause of morbidity and mortality in the United States, with in-stent restenosis (ISR) posing a significant challenge following percutaneous coronary intervention (PCI). Drug-eluting stents (DES) have been widely used to mitigate ISR; however, until recently, no drug-coated balloon (DCB) catheter had been approved for use in the United States. The US Food and Drug Administration (FDA) has now approved AGENT DCB, a paclitaxel-coated balloon catheter, offering a novel approach to treating ISR.Hypothesis The approval of AGENT DCB represents a pivotal advancement in PCI, providing an effective alternative to traditional balloon angioplasty for ISR.Methods This article is an editorial review and does not involve original research, statistical analysis, or software-based evaluations. The findings and discussion are based on the results of the AGENT IDE trial and related literature on the efficacy of DCB catheters in the treatment of ISR.Results The AGENT IDE trial, a randomized, multicenter study involving 600 participants across 40 US sites, demonstrated that the paclitaxel-coated balloon group had a significantly lower target lesion failure rate at 12 months compared to the uncoated balloon group (17.9% vs. 28.6%, p = 0.003). The reduction was primarily driven by a lower incidence of target lesion revascularization (13.0% vs. 24.7%, p = 0.001) and myocardial infarction related to the target vessel (5.8% vs. 11.1%, p = 0.02). Additionally, no cases of stent thrombosis were observed in the DCB group compared to 3.2% in the control group (p = 0.001), reinforcing the device's safety and efficacy.Conclusions The FDA approval of AGENT DCB marks a significant milestone in the management of ISR, offering a promising alternative to conventional interventions. With its ability to deliver antiproliferative therapy while avoiding the complications associated with permanent stents, DCB may revolutionize PCI strategies in the United States. Further studies assessing the long-term impact of this technology, as well as its application in broader patient populations, will be essential to solidify its role in clinical practice.
SN - 0160-9289
SN - 1932-8737
ER -